Oxford Immunotec Global PLC (NASDAQ:OXFD) Position Raised by Parkwood LLC

Parkwood LLC increased its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 12.9% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 12,799 shares of the company’s stock after buying an additional 1,465 shares during the period. Parkwood LLC owned about 0.06% of Oxford Immunotec Global PLC worth $215,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Endurant Capital Management LP raised its position in Oxford Immunotec Global PLC by 3,456.1% in the first quarter. Endurant Capital Management LP now owns 570,971 shares of the company’s stock worth $8,844,000 after buying an additional 554,915 shares during the last quarter. AXA raised its position in Oxford Immunotec Global PLC by 52.5% in the first quarter. AXA now owns 917,468 shares of the company’s stock worth $14,212,000 after buying an additional 315,718 shares during the last quarter. Redmile Group LLC raised its position in Oxford Immunotec Global PLC by 17.9% in the first quarter. Redmile Group LLC now owns 2,004,849 shares of the company’s stock worth $31,055,000 after buying an additional 303,800 shares during the last quarter. Granahan Investment Management Inc. MA purchased a new position in Oxford Immunotec Global PLC during the first quarter worth about $4,577,000. Finally, Renaissance Technologies LLC raised its position in Oxford Immunotec Global PLC by 97.8% in the first quarter. Renaissance Technologies LLC now owns 363,300 shares of the company’s stock worth $5,628,000 after buying an additional 179,600 shares during the last quarter. Institutional investors and hedge funds own 87.47% of the company’s stock.

Oxford Immunotec Global PLC (NASDAQ OXFD) traded up 2.33% during trading on Friday, reaching $17.55. The company’s stock had a trading volume of 19,449 shares. The firm’s market cap is $402.35 million. Oxford Immunotec Global PLC has a 52 week low of $8.88 and a 52 week high of $19.51. The stock’s 50 day moving average is $16.18 and its 200-day moving average is $14.93.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.32). The company had revenue of $26.10 million during the quarter, compared to the consensus estimate of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 113.22% and a negative net margin of 64.19%. The company’s revenue for the quarter was up 35.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.29) earnings per share. On average, equities research analysts forecast that Oxford Immunotec Global PLC will post ($1.07) earnings per share for the current fiscal year.

OXFD has been the topic of a number of research analyst reports. Zacks Investment Research lowered Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. BTIG Research reaffirmed a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Thursday, May 4th. ValuEngine raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Piper Jaffray Companies reissued a “buy” rating and issued a $26.00 price target on shares of Oxford Immunotec Global PLC in a research note on Thursday. Finally, Cowen and Company reissued a “buy” rating and issued a $22.00 price target on shares of Oxford Immunotec Global PLC in a research note on Thursday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $21.00.

In related news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $14.40, for a total transaction of $43,200.00. Following the completion of the transaction, the director now directly owns 20,174 shares of the company’s stock, valued at $290,505.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Elizabeth M. Keiley sold 4,085 shares of the stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $15.01, for a total value of $61,315.85. Following the transaction, the vice president now directly owns 25,393 shares of the company’s stock, valued at $381,148.93. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 147,085 shares of company stock valued at $2,275,928. 7.58% of the stock is owned by corporate insiders.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).